Richard A. Larson to Topotecan
This is a "connection" page, showing publications Richard A. Larson has written about Topotecan.
Connection Strength
0.194
-
Treatment of myelodysplastic syndrome with 2 schedules and doses of oral topotecan: a randomized phase 2 trial by the Cancer and Leukemia Group B (CALGB 19803). Cancer. 2009 Jan 01; 115(1):84-93.
Score: 0.082
-
Pharmacokinetics, pharmacodynamics and adherence to oral topotecan in myelodysplastic syndromes: a Cancer and Leukemia Group B study. Cancer Chemother Pharmacol. 2006 Jan; 57(2):199-206.
Score: 0.065
-
New agents for induction and postremission therapy of acute myeloid leukemia. Leukemia. 2001 Apr; 15(4):675-6.
Score: 0.048